Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Open accessThe DOI matches its Crossref record; 130 of the 132 references it cites were found in a registry or an index; 128 of the 188 sources its claims cite were checked for support.
Abstract
The advent of induced pluripotent stem cells (iPSCs) has advanced our understanding of the molecular mechanisms of human disease, drug discovery, and regenerative medicine. As such, the use of iPSCs in drug development and validation has shown a sharp increase in the past 15 years. Furthermore, many labs have been successful in reproducing many disease phenotypes, often difficult or impossible to capture, in commonly used cell lines or animal models. However, there still remain limitations such as the variability between iPSC lines as well as their maturity. Here, we aim to discuss the strategies in generating iPSC-derived cardiomyocytes and neurons for use in disease modeling, drug development and their use in cell therapy.
Overview
CoChat Summary
TL;DR
This review discusses how induced pluripotent stem cell (iPSC)-derived cardiomyocytes, neurons, and organoids are used for disease modeling, drug discovery, and cell therapy, with emphasis on cardiovascular and neurological applications. It also covers remaining hurdles including iPSC line variability, cell immaturity, and immune rejection in transplantation.
Key findings
- iPSC-derived cardiomyocytes recapitulate cardiac channelopathies and cardiomyopathies and have enabled drug discovery: e.g., nicorandil and PD118057 shortened action potentials in type-2 LQTS cells, mexiletine analogues enhanced INa potency/selectivity for type-3 LQTS, and verapamil showed the strongest inhibition of contractile function among four calcium channel blockers tested in HCM cells.
- iPSC-derived neurons model AD, PD, ALS, ASD, and SMA; examples include docosahexaenoic acid alleviating stress responses in AD neurons, Coenzyme Q10/rapamycin/GW5074 in LRRK2- and PINK1-mutant PD cells, ropinirole in TDP-43/FUS ALS motor neurons, and IGF-1 or hyperforin rescuing TRPC6-mutant ASD neuronal abnormalities.
- Organoid platforms support screening: >10,000 cardiac organoids were screened to identify optimal maturation conditions; >1000 FDA-approved drugs were screened in hPSC-forebrain organoids, identifying hippeastrine hydrobromide against ZIKV; a 50,000-compound screen in fragile X neuronal progenitors identified compounds inducing FMRP expression.
- HLA-homozygous iPSC banking can cover large populations from few donors: 55 donors for ~80% of the Japanese population, 150 iPSC lines for ~93% of the UK, 140 lines for ~90% of Japan, and ~80 lines for 50% coverage in California; CiRA's three clinical-grade lines cover 32% of Japan, Korea's 10 lines cover 41%, and Taiwan's 13 lines cover ~16% of Taiwanese.
Methods
- Narrative review (no primary data collection) covering iPSC generation and differentiation into cardiomyocytes, neurons, and organoids for disease modeling, drug discovery, and cell therapy.
- Synthesizes published preclinical and clinical studies, including high-throughput screening studies, HLA banking calculations, and CRISPR/Cas9 genome-editing approaches.
- Includes a table (Table 1) outlining iPSC-based clinical trials current as of 2021.
Limitations
- Stated by the paper: iPSC-derived cells are immature and lack intercellular communication, making complex adult disease mimicry difficult; many diseases are polygenic/heterogeneous (e.g., ASD) so a single patient line may not yield a single hit compound; reprogramming and differentiation protocol reproducibility is a recurring issue; 5–46% of phenotypic variability in iPSCs stems from normal human genetic variation (inter- and intraclone); high-throughput miniaturization challenges include low cell numbers, media evaporation, and low-volume dispensing accuracy; organoids represent fetal-like rather than adult structures; CRISPR/Cas9 off-target cleavage risks oncogenic mutations; HLA-edited cells carry increased tumorigenicity risk; autologous transplantation is time-consuming and expensive.
- Evident from the text: the review is descriptive and does not present new experimental data; several cited clinical trials (e.g., Help Therapeutics Phase 1/2, Cuorips/Osaka Phase 1) lacked efficacy data at the time of writing.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
87 Valid · 19 Not valid · 34 Not checked · 39 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Using iPSC-derived cardiomyocytes from type-3 LQTS patients with SCN5A mutation revealed abnormal calcium transients with diminished INa current density [11].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 2. Drug Discovery Using iPSC-Derived Disease Models > 2.1. Cardiomyocytes
What the sources say
- Disputedcites [11] Hong L. Zhang M. Ly O.T. Chen H. Sridhar A. Lambers E. Chalazan B. Youn S.-W. Maienschein-Cline M. Feferman L. Human induced pluripotent stem cell-derived atrial cardiomyocytes carrying an SCN5A mutation identify nitric oxide signaling as a mediator of atrial fibrillation Stem Cell Rep. 2021 16 1542 1554 10.1016/j.stemcr.2021.04.019 34019817 PMC8190590 sourceExperimental — accuracy not yet measured
The Results section on AF iPSC-aCMs reports abnormal calcium transients in SCN5A-mutant atrial cardiomyocytes, but these were studied in an atrial-fibrillation model, not cells from type-3 LQTS patients. The same section reports no significant change in sodium-current amplitude and a marked increase in late sodium current (INa,L), contrary to the claimed diminished INa current density. Page numbers are unavailable in our copy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The capacity of iPSCs for the scalable production of diverse cell types benefits researchers by reducing obstacles with procedures such as apheresis, which involves separating specific components from the blood and retuning the remaining components to the donor’s circulation, whilst obtaining human cells [3].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 1. Introduction
What the sources say
- Partly supportedcites [3] Carvajal-Vergara X. Sevilla A. D’Souza S.L. Ang Y.S. Schaniel C. Lee D.F. Yang L. Kaplan A.D. Adler E.D. Rozov R. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome Nature 2010 465 808 812 10.1038/nature09005 20535210 PMC2885001 sourceExperimental — accuracy not yet measured
The paper reports that patient-derived iPSCs differentiated into multiple cell types and describes iPSC-derived cells as a resource for studying disease (Abstract; page unavailable). It does not establish scalable production or say that iPSCs reduce obstacles associated with apheresis; its patient cells were obtained from skin biopsies (Methods Summary, Cell culture; page unavailable). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Various cell models built with iPSC derivatives have been shown to resemble in vivo or primary cell counterparts at transcriptional, cellular, and functional levels whilst leaving little interference to the genetic content [4,5,6,7].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 1. Introduction
What the sources say
- Partly supportedcites [4] Caspi O. Huber I. Gepstein A. Arbel G. Maizels L. Boulos M. Gepstein L. Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells Circ. Cardiovasc. Genet. 2013 6 557 568 10.1161/CIRCGENETICS.113.000188 24200905 sourceExperimental — accuracy not yet measured
The Generation of the ARVC Patient-Specific hiPSCs section reports that the cells retained the patient’s PKP2 mutation and had a normal karyotype. CM Differentiation reports cardiac gene expression, cell markers, and electrical activity; the Discussion says the derived cells reproduced key ARVC pathology. These findings support resemblance in this disease model, but the paper does not establish that producing iPSC-derived models causes little interference with genetic content generally. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [5] Moretti A. Bellin M. Welling A. Jung C.B. Lam J.T. Bott-Flügel L. Dorn T. Goedel A. Höhnke C. Hofmann F. Patient-specific induced pluripotent stem-cell models for long-QT syndrome N. Engl. J. Med. 2010 363 1397 1409 10.1056/NEJMoa0908679 20660394 source
- Not checked — no full text of the sourcecites [6] Egashira T. Yuasa S. Suzuki T. Aizawa Y. Yamakawa H. Matsuhashi T. Ohno Y. Tohyama S. Okata S. Seki T. Disease characterization using LQTS-specific induced pluripotent stem cells Cardiovasc. Res. 2012 95 419 429 10.1093/cvr/cvs206 22739119 source
- Not checked — no full text of the sourcecites [7] Itzhaki I. Maizels L. Huber I. Zwi-Dantsis L. Caspi O. Winterstern A. Feldman O. Gepstein A. Arbel G. Hammerman H. Modelling the long QT syndrome with induced pluripotent stem cells Nature 2011 471 225 229 10.1038/nature09747 21240260 source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Even though rigorous testing is undertaken during the development stages, 90% of drugs fail clinical trials [2].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 1. Introduction
What the sources say
- Could not verifycites [2] Li S. Pan H. Tan C. Sun Y. Song Y. Zhang X. Yang W. Wang X. Li D. Dai Y. Mitochondrial Dysfunctions Contribute to Hypertrophic Cardiomyopathy in Patient iPSC-Derived Cardiomyocytes with MT-RNR2 Mutation Stem Cell Rep. 2018 10 808 821 10.1016/j.stemcr.2018.01.013 PMC5918198 29456182 sourceExperimental — accuracy not yet measured
The Introduction discusses the difficulty of obtaining patient cardiomyocytes, and the Experimental Procedures describe cell-based experiments; neither addresses clinical-trial outcomes. Searches for the 90% figure and for drug-development failure rates found no supporting passage in our copy. (LLM, conf=0.75)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The physiological and genetic differences between human and animals leads to potential differences in terms of function, mechanisms, and signaling pathways [14,15].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 2. Drug Discovery Using iPSC-Derived Disease Models
What the sources say
- Partly supportedcites [14] Lan F. Lee A.S. Liang P. Sanchez-Freire V. Nguyen P.K. Wang L. Han L. Yen M. Wang Y. Sun N. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells Cell Stem Cell 2013 12 101 113 10.1016/j.stem.2012.10.010 23290139 PMC3638033 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) explains that human and mouse hearts predominantly use different myosin isoforms and that the same HCM mutation can have different functional consequences in those isoforms. This supports the claim about potential functional differences, but the paper does not establish a general human–animal difference in mechanisms or signaling pathways. (LLM, conf=0.86)
- Partly supportedcites [15] Han L. Li Y. Tchao J. Kaplan A.D. Lin B. Li Y. Mich-Basso J. Lis A. Hassan N. London B. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells Cardiovasc. Res. 2014 104 258 269 10.1093/cvr/cvu205 25209314 PMC4217687 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that mouse models cannot represent the genetic diversity of human hypertrophic cardiomyopathy and that patient-specific disease mechanisms need study. It does not establish that physiological differences between humans and animals cause differences in function or signaling pathways. (LLM, conf=0.82)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
100 more claims · 53 with their cited sources checked
Create a free account to see all 179 claims and every source verdict.
- It may state two separate claims as one. 54
- Probably not a substantial claim. 27
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 3. iPSC-Based Cell Therapy > 3.1. HLA-Homozygous iPSC Banking
“This was confirmed in mice showing that iPSC-derived cell implantation leads to cellular apoptosis and T cell proliferation [94].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > References
“94. Guha P. Morgan J.W. Mostoslavsky G. Rodrigues N.P. Boyd A.S. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells Cell Stem Cell 2013 12 407 412”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 2. Drug Discovery Using iPSC-Derived Disease Models > 2.2. Neurons
“Ohuchi et al., 2006, first used SMA patient iPSC-derived motor neurons and astrocytes”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > References
“51. Ohuchi K. Funato M. Kato Z. Seki J. Kawase C. Tamai Y. Ono Y. Nagahara Y. Noda Y. Kameyama T. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog Stem Cells Transl. Med. 2016 5 152 163”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 3. iPSC-Based Cell Therapy
“Other notable Phase 1 clinical trials in Japan includes an iPSC-derived cardiomyocyte sheet from a group comprising Cuorips Inc. and Osaka University [90]; their preclinical studies on ischemic cardiomyopathy pig models have shown improved cardiac function”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > References
“90. Doi D. Magotani H. Kikuchi T. Ikeda M. Hiramatsu S. Yoshida K. Amano N. Nomura M. Umekage M. Morizane A. Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson’s disease Nat. Commun. 2020 11 3369”
Citations
Cites
Cerebral organoids model human brain development and microcephaly
Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372 · cited 1×
“These 3D “organoids” are often found to have instructive morphogenetic cues resulting in self organization similarly found in vivo [53,54].”
BackgroundDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380 · cited 1×
“NK cells, which act as important immune cells, are widely used for transplantation [82,83].”
BackgroundDouble nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096 · cited 1×
“These models have been particularly important in the search for anticancer compounds as they can predict patient outcomes in phase 1/2 clinical trials for gastrointestinal cancer [55].”
BackgroundA more efficient method to generate integration-free human iPS cells
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K.-I., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1591 · Cited by 2,061
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624
Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration
Mandai, M., Watanabe, A., Kurimoto, Y., Hirami, Y., Morinaga, C., Daimon, T., Fujihara, M., Akimaru, H., Sakai, N., Shibata, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608368 · Cited by 1,509
Cited by
Wang, L., Wang, B., Wu, C., Wang, J., & Sun, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031819 · Cited by 237
“2 Duplication ↓spontaneous neuronal activity and calcium signalling; ↓expression of miR-1290 [53]”
BackgroundExploring the promising potential of induced pluripotent stem cells in cancer research and therapy
Chehelgerdi, M., Behdarvand Dehkordi, F., Chehelgerdi, M., Kabiri, H., Salehian-Dehkordi, H., Abdolvand, M., Salmanizadeh, S., Rashidi, M., Niazmand, A., Ahmadi, S., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01873-0 · Cited by 175
Revolutionizing Disease Modeling: The Emergence of Organoids in Cellular Systems
Silva-Pedrosa, R., Salgado, A. J., & Ferreira, P. E. (2023) · Cells · doi:10.3390/cells12060930 · Cited by 84
“This can greatly accelerate the drug development process and ultimately lead to new treatments for patients [46,47].”
BackgroundProgress in Organ Bioprinting for Regenerative Medicine
Wang, X. S., Zhang, D., Singh, Y. P., Yeo, M., Deng, G., Lai, J., Chen, F., Ozbolat, I. T., & Yu, Y. (2024) · Engineering · doi:10.1016/j.eng.2024.04.023 · Cited by 70
“Recent studies have differentiated iPSCs into cells of various lineages such as CMs, neurons, hepatic cells, and ECs [85,86], The field of bioprinting has witnessed a trend of utilizing iPSC-derived cells, such as for the fabrication of cardiac [87], hepatic [43], and pancreatic [88] tissues.”
A Review of Advanced Biomaterials and Cells for the Production of Bone Organoid
Li, C., Zhang, Y., Du, Y., Hou, Z., Zhang, Y., Cui, W., & Chen, W. (2023) · Small Science · doi:10.1002/smsc.202300027 · Cited by 34
Metadata
- Authors
- Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H.
- Affiliations
- Institute of Biomedical Sciences, Academia Sinica (TW)
- Corresponding author
- Hsieh, Patrick C. H.
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2022-06-06
- Volume
- 11
- Issue
- 11
- Pages
- 1853
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9180434
- OpenAlex
- W4281701292
- Cited by
- 65
- References
- 132
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 15 · 2023: 17 · 2022: 2
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- induced pluripotent stem cells, iPSC-derived cardiomyocytes, iPSC-derived neurons, disease modeling, drug development, cell therapy, regenerative medicine
- MeSH terms
- Drug Development, Animals, Pluripotent Stem Cells, Regenerative Medicine, Induced Pluripotent Stem Cells, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
